Evaluation of therapeutic efficiency of hilsha fish oil on cardiovascular disease and hepatic disease marker in hypercholesterolemic mice Article

Munira, S, Asaduzzaman, M, Sohanur Rahman, M et al. (2015). Evaluation of therapeutic efficiency of hilsha fish oil on cardiovascular disease and hepatic disease marker in hypercholesterolemic mice . 7(5), 10.4172/0974-8369.1000254

cited authors

  • Munira, S; Asaduzzaman, M; Sohanur Rahman, M; Muedur Rahman, M; Hasan, M; Biswas, S; Islam, M; Mamun, MA; Khan, MMH; Rahman, MM; Karim, MR; Islam, MA

abstract

  • Hypercholesterolemia is a clinical situation characterized by the elevated serum cholesterol and associated with the higher risk of cardiovascular disease (CVD), hypertension and stroke. This study aimed to evaluate the therapeutic eficiency of hilsha ish (Tenualosa ilisha) oil on diet-induced hypercholesterolemic (HC) albino mice. Mice were divided in three groups consisting each of six mice: control group, HC control group (fed the basal diet containing 1.5% cholesterol and 0.5% cholic acid) and the other group of mice fed the same previous hypercholesterolemic diet supplemented with hilsha ish oil (HFO) 5%. Serum lipid proile (total cholesterol-TC, low density lipoprotein-LDL, high density lipoprotein- HDL, triglyceride-TG and very low density lipoprotein-VLDL) were determined using commercial kits. After treatment with HFO a potential antilipidemic effect was observed as TC, TG, LDL, VLDL showed signiicant (p<0.001) decrease whereas HDL showed signiicant increase (p<0.001) compared to the HC control group. The SGPT, SGOT and CRP were also signiicantly decrease (p<0.001). Therefore HFO might have hepatoprotective activity. Regarding liver tissue extract, the levels of total cholesterol and triglyceride were decreased signiicantly in treated mice. Gas chromatography (GC)-MS analysis of HFO showed that it contained a high amount of poly unsaturated fatty acids (PUFA) especially EPA and DHA. These Omega-3 fatty acids have an indicative effect to reduce the risk of CVD and other chronic diseases. From the above indings, it can be concluded that HFO has a potential beneit in the treatment of CVD and play a role in its management as well as in reducing the risk of CVD associated hepatic complications.

publication date

  • January 1, 2015

Digital Object Identifier (DOI)

volume

  • 7

issue

  • 5